Summary
Twenty patients with advanced measurable, squamous carcinoma of the cervix were treated with 25 courses of N-MF at doses ranging from 600–800 mg/m2, intravenously, daily for 5 days every 28 days. Nineteen patients are evaluable for toxicity and 17 for response. All patients had prior radiation and had received one prior chemotherapy regimen while only 10 patients had had prior surgery. All patients were Gynecologic Oncology Group (GOG) performance status 0, 1, or 2. No responses were seen. Hematologic adverse effects were extremely rare as predicted by early clinical trials. One unusual toxicity was a syndrome consisting of pain, anorexia, lethargy, and declining performance status (pain/lethargy syndrome) that was reversible with discontinuation of the drug. This adverse effect was a reason for discontinuation of N-MF in two patients. As reported in previous studies with this drug, hepatic toxicity was also common, usually reversible, and also a cause for discontinuation of the drug. The lack of clinical activity and the unpleasant adverse effects in this population of patients with previously treated cervix cancer makes it unlikely that this drug will play any significant role in treatment.
Similar content being viewed by others
References
Tanaka M, Levy J, Terada M, Breslow R, Rifkind RA, Marks PA: Induction of erythroid differentiation in murine virus-infected erythroleukemia cells by highly polar compounds. Proc Natl Acad Sci 72: 1003–1006, 1975
Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC: Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci 75: 2458–2462, 1978
National Cancer Institute: N-methylformamide. Bethesda, MD, NCI Clinical Brochure, 1982
National Cancer Institute: N-methylformamide. Bethesda, MD, Report to the Food and Drug Administration, 1985
McVie JG, ten Bokkel Huiniuk WW, Simonetti G, Dubbelman R: Phase I trial of N-methylformamide. Cancer Treat Rep 68: 607–610, 1984
Vogel WC, Forastiere AA, Natale RB, Takasugi BJ, Schnur G: Phase II trial of N-methylformamide in advanced head and neck cancer. Invest New Drugs 5: 203–206, 1987
Sternberg CN, Yagoda A, Scher HI, Hollander P: Phase II trial of N-methylformamide for advanced renal cell carcinoma. Cancer Treat Rep 70: 681–682, 1986
Tchekmedyian NS, Kaplan RS, Eisenberger M, Abrams J, Van Echo D: Phase II study of N-methylformamide in patients with advanced colorectal cancer. Cancer Treat Rep 71: 541–542, 1987
Author information
Authors and Affiliations
Additional information
The following are participating institutions and the National Cancer Institute grants supporting this study: University of Alabama at Birmingham (CA 12484), Temple University Health Science Center Hospital (CA 27816), University of Minnesota Medical School (CA 23088), University of Southern California Medical Center at Los Angeles (CA 37535), University of California Medical Center at Los Angeles (CA 13630), University of Texas Health Science Center at Dallas (CA 28160), Bowman Gray School of Medicine of Wake Forest University (CA 21946), University of California Medical Center at Irvine (CA 23765), Tufts New England Medical Center (CA 37569), The Johns Hopkins Oncology Center, and Pennsylvania Hospital.
Unfunded.
Address for offprints: GOG Headquarters, Suite 1945, 1234 Market Street, Philadelphia, PA 19107, USA
Rights and permissions
About this article
Cite this article
McGuire, W.P., Blessing, J.A., Hatch, K.D. et al. Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced squamous cancer of the cervix. Invest New Drugs 8, 195–197 (1990). https://doi.org/10.1007/BF00177258
Issue Date:
DOI: https://doi.org/10.1007/BF00177258